NCT04624854

Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8,250 (actual)
• Sponsor: Harbin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least 12 months after being implanted with a drug-eluting stent (DES) at one of 100 different centers. All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a permuted completely randomization.

Conditions

• Coronary Artery Disease
• Myocardial Ischemia
• Acute Coronary Syndrome
• Heart Diseases
• Syndrome Heart Disease
• Cardiovascular Diseases
• Arteriosclerosis
• Arterial Occlusive Diseases
• Coronary Disease
• Vascular Diseases

Interventions

Type	Name	Description
DRUG	Clopidogrel and aspirin dual-antiplatelet therapy	Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
DRUG	Aspirin monotherapy	Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.

Timeline

• Start date: 2020-10-28
• Primary completion: 2025-09-23
• Completion: 2025-09-23
• First posted: 2020-11-12
• Last updated: 2025-12-01

Locations

97 sites across 1 country: China